Download video

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung Cancer

420 views

GRACE - Global Resource for Advancing Cancer Education

1 year ago

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung Cancer

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung Cancer

ADAURA Trial: Tagrisso \& Resectable EGFR+ - Leading Developments \& Current Questions in Lung Cancer
5:12
ADAURA Trial: Tagrisso \& Resectable EGFR+ - Leading Developments \& Current Questions in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education
The ADAURA Trial: Flaws and Results - Leading Developments \& Current Questions in Lung Cancer
11:41
The ADAURA Trial: Flaws and Results - Leading Developments \& Current Questions in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education
Key Points from the Adaura Trial: Osimertinib - Targeted Therapies in Lung Cancer 2023
5:54
Key Points from the Adaura Trial: Osimertinib - Targeted Therapies in Lung Cancer 2023
by GRACE - Global Resource for Advancing Cancer Education
The Adaura Trial: The Effect on EGFR+ Treatment - Targeted Therapies in Lung Cancer 2023
6:06
The Adaura Trial: The Effect on EGFR+ Treatment - Targeted Therapies in Lung Cancer 2023
by GRACE - Global Resource for Advancing Cancer Education
Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial
2:20
Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial
by OncoInfoTV
The ADAURA Trial: 2023 Updates - Targeted Therapies in Lung Cancer 2023
6:00
The ADAURA Trial: 2023 Updates - Targeted Therapies in Lung Cancer 2023
by GRACE - Global Resource for Advancing Cancer Education
ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum
2:06
ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum
by GRACE - Global Resource for Advancing Cancer Education
Perioperative Keytruda for Early Stage NSCLC-Leading Developments \& Current Questions in Lung Cancer
6:00
Perioperative Keytruda for Early Stage NSCLC-Leading Developments \& Current Questions in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education
Five Year Update on ADAURA Clinical Trial of Tagrisso in EGFR Early Stage NSCLC.
4:10
Five Year Update on ADAURA Clinical Trial of Tagrisso in EGFR Early Stage NSCLC.
by OMNIConnect
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
5:03
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
by ecancer
ADAURA: osimertinib adjuvant therapy on CNS disease recurrence
3:30
ADAURA: osimertinib adjuvant therapy on CNS disease recurrence
by VJOncology
Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer
10:38
Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education
Chemo +\/- Immunotherapy for Mesothelioma-Leading Developments \& Current Questions in Lung Cancer
6:08
Chemo +\/- Immunotherapy for Mesothelioma-Leading Developments \& Current Questions in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education
ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC
2:33
ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC
by VJOncology
ADAURA: the benefit of adjuvant osimertinib
1:42
ADAURA: the benefit of adjuvant osimertinib
by VJOncology
2020 TTF EGFR QA PANEL Updates Combo Treatment of Osimertinib (Tagrisso) \& Ramucirumab (Cyramza)
2:06
2020 TTF EGFR QA PANEL Updates Combo Treatment of Osimertinib (Tagrisso) \& Ramucirumab (Cyramza)
by GRACE - Global Resource for Advancing Cancer Education
ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC
4:25
ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC
by OncLive
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
6:20
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
by European Society for Medical Oncology (ESMO)